MDB Capital Group
MDB Capital Group, LLC is Wall Street’s only IP-driven public venture bank, with over 15 years of experience launching disruptive technologies into the public markets. We maximize the value of disruptive technology companies by positioning them to attract growth capital, strengthening their IP portfolios to create sustainable competitive advantage, and connecting them with a base of high-quality investors with deep technology expertise. To support these efforts, we created PatentVest®, a fully-integrated analytic and reporting platform that measures, scores and ranks every patent and application in the USPTO database. Seeing value others do not. Creating value others cannot.
MDB Capital Group CEO Chris Marlett on Bloomberg TV, discussing the recent Apple-Samsung patent lawsuit.
Play video >
Is the offer to buy BlackBerry merely meant to start a bidding war?
Chris Marlett, CEO of MDB Capital Group, talks with Julianne Pepitone at CNNMoney.
November 19, 2014
SYLMAR, CALIFORNIA, November 19, 2014 – Second Sight Medical Products, Inc. (Second Sight) today announced the pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share. Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. Its current product, the Argus® II System, which treats outer retinal degenerations such as retinitis pigmentosa, is the only retinal prosthesis approved in the United States by the FDA and the first approved retinal prosthesis in the world | read more...